Rema, João PauloCouto, Frederico Simões do2022-05-092022-05-092022-03-222184-5417http://hdl.handle.net/10400.14/37455porAnticorpos monoclonais humanizadosDoença de Alzheimer/tratamento farmacológicoAlzheimer Disease/drug therapyAntibodiesMonoclonalHumanizedAducanumab na doença de Alzheimer: percurso e perspetivaAducanumab for Alzheimer’s disease: course and overviewjournal article10.51338/rppsm.308